Comparative Pharmacology
Head-to-head clinical analysis: CALAN versus CALAN SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALAN versus CALAN SR.
CALAN vs CALAN SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Oral: 180–240 mg once daily; maximum 480 mg/day.
None Documented
None Documented
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker